Short answer
HAEMONETICS CORP (HAE) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 27, 2026. Quarterly revenue was $339M (up 5.6% year over year) with net income of $33M.
Q2 2026 key financials · XBRL
- Revenue
- $339M
- +5.6% YoY
- Net income
- $33M
- −3.0% YoY
- Operating margin
- 16.9%
- Gross margin
- 59.8%
- EPS (diluted)
- $0.72
- +2.9% YoY
Source: XBRL data from the HAEMONETICS CORP (HAE) Q2 2026 10-Q on SEC EDGAR. USD.
HAEMONETICS CORP Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $339.4M, up 5.6% YoY from $321.4M
- Operating margin 16.9% vs 16.8%; net margin 9.7% vs 10.6%
- Best segment MedSurg, revenue $148.1M, up 6.0%; Blood Management Technologies up 8.6%
- Worst line Apheresis Other, revenue $35.8M, down 2.4% YoY
- Operating cash flow $52.3M vs $17.4M; $50.0M revolving-credit repayment drove financing outflows of $51.5M
Risk Factors
- No material risk-factor changes from March 28, 2026 Form 10-K
- Carried-forward operational, competitive, and market risks remain as disclosed in the 10-K
- Carried-forward regulatory, legal, and compliance risks remain as disclosed in the 10-K
- Carried-forward liquidity, debt, currency, and concentration risks remain as disclosed in the 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HAEMONETICS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.